Immune-mediated diabetes associated with pembrolizumab.
Bodoque Cubas J, Salazar González JJ, Miret Llauradó M.
Med Clin (Barc). 2023 Jul 7;161(1):39-40. doi: 10.1016/j.medcli.2023.02.013. Epub 2023 Mar 31.
Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments.
Antar SA, Ashour NA, Sharaky M, Khattab M, Ashour NA, Zaid RT, Roh EJ, Elkamhawy A, Al-Karmalawy AA.
Biomed Pharmacother. 2023 Dec;168:115734. doi: 10.1016/j.biopha.2023.115734. Epub 2023 Oct 17.
Anti-Islet Autoantibodies in Type 1 Diabetes.
Kawasaki E.
Int J Mol Sci. 2023 Jun 11;24(12):10012. doi: 10.3390/ijms241210012.
Type 1 diabetes-early life origins and changing epidemiology.
Norris JM, Johnson RK, Stene LC.
Lancet Diabetes Endocrinol. 2020 Mar;8(3):226-238. doi: 10.1016/S2213-8587(19)30412-7. Epub 2020 Jan 27.
Diabetes mellitus-Progress and opportunities in the evolving epidemic.
Abel ED, Gloyn AL, Evans-Molina C, Joseph JJ, Misra S, Pajvani UB, Simcox J, Susztak K, Drucker DJ.
Cell. 2024 Jul 25;187(15):3789-3820. doi: 10.1016/j.cell.2024.06.029.
Current and future therapies for type 1 diabetes.
von Scholten BJ, Kreiner FF, Gough SCL, von Herrath M.
Diabetologia. 2021 May;64(5):1037-1048. doi: 10.1007/s00125-021-05398-3. Epub 2021 Feb 17.
Genetics of type 1 diabetes.
Redondo MJ, Steck AK, Pugliese A.
Pediatr Diabetes. 2018 May;19(3):346-353. doi: 10.1111/pedi.12597. Epub 2017 Nov 2.
Pancreatic beta-cells in type 1 and type 2 diabetes mellitus: different pathways to failure.
Eizirik DL, Pasquali L, Cnop M.
Nat Rev Endocrinol. 2020 Jul;16(7):349-362. doi: 10.1038/s41574-020-0355-7. Epub 2020 May 12.
New Frontiers in the Treatment of Type 1 Diabetes.
Warshauer JT, Bluestone JA, Anderson MS.
Cell Metab. 2020 Jan 7;31(1):46-61. doi: 10.1016/j.cmet.2019.11.017. Epub 2019 Dec 12.
Autonomic Peripheral Neuropathy.
Freeman R.
Continuum (Minneap Minn). 2020 Feb;26(1):58-71. doi: 10.1212/CON.0000000000000825.
